Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Phase 2

Not yet recruiting

• Conditions: Chronic Lymphocytic Leukemia; CLL Variant; Small Lymphocytic Lymphoma
• Interventions: Drug: Venetoclax; Drug: Acalabrutinib

• Registration Number: NCT07014917
• Lead Sponsor: Zulfa Omer

Brief Summary

This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Detailed Description

This study is a two-arm, open label, Phase II multicenter clinical trial designed to evaluate the intermittent and continuous venetoclax + acalabrutinib in 2 arms in previously untreated CLL/SLL.

Phase II trial will be in two separate arms using Simon's 2-stage design for each. Subjects will be randomized with 2:1 ratio into Arm A which will receive intermittent venetoclax (7days administration per cycle) + acalabrutinib and Arm B which will receive continuous venetoclax (28 days administrations per cycle) + acalabrutinib.

With this trial we are seeking to establish efficacy of the combination therapy in both treatment models (intermittent and continuous venetoclax) and to acquire pilot data characterizing the effectiveness of the combination in increasing the depth of response as reflected in the rate of uMRD CR. We will reject the null hypothesis for each arm separately if CR at Cycle 12 obtained in 8 patients in Arm A and 5 patients in Arm B and move forward for a larger phase 3 study.

A continuous toxicity monitoring model to monitor adverse events will be used. This model has been used successfully with phase II trials designed with the Simon 2-Stage. This methodology will allow us to monitor the cumulative number of toxic events after each patient is treated and hence to stop the study if the drug toxicities exceeded the prespecified toxicity boundary.

Study Timeline

• Study First Submitted: 2025-05-05
• Status Verified: 2025-06
• Study Start: 2025-06-01
• Study First Submitted QC: 2025-06-02
• Last Update Submitted: 2025-06-02
• Study First Posted: 2025-06-11
• Last Update Posted: 2025-06-11
• Primary Completion: 2028-06-01
• Study Completion: 2032-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

1. Diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) as defined by the IWCLL including variation of flow cytometry, provided cytogenetic or mutational data are supportive of CLL/SLL diagnosis that requires therapy by one IWCLL criteria; and, must be previously untreated CLL/SLL.

   a. Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface expression of CD79b that is bright) but clinically behave like CLL (leukocytosis, lymphadenopathy and splenomegaly) and have the FISH/Cytogenetics translocations (del 13q, trisomy 12, Del11q) or genomic features (XPO1, NOTCH1, SF3B1, FBXW7, MYD88, BIRC3, TRAF3, NFKBIE, SAMHD1, POT1, HIST1H1E, CHD2, ZMYM3, EGR2 and others) that are suggestive of CLL

2. Men and Women ≥18 years of age.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.

4. Subjects must have adequate organ and marrow function as defined below:

   1. ANC ≥1,000/mcL, unless if neutropenia is due to extensive underlying CLL bone marrow disease then platelet threshold will be ANC ≥500/mcL unless WBC is > to 50 x 109/L. If WBC is > to 50 x 109/L there will be no lower threshold of ANC. Use of steroids for disease control is allowed.
   2. Platelets ≥30,000/mcL unless thrombocytopenia is due to extensive underlying CLL bone marrow disease platelets threshold will be ≥ 10, 000/mcl. Use of steroids for disease control is allowed.
   3. Total bilirubin ≤1.5 x ULN unless directly attributable to Gilbert's syndrome
   4. AST and ALT ≤3 × ULN
   5. Creatinine clearance (Cockcroft) ≥30 mL/min/1.73 m2 • CrCl by Cockcroft and Gault method: CrCl (mL/min) = (140 - age [years]) × weight (kg) × (F)a (72 × serum creatinine mg/dL a where F = 0.85 for females and F = 1 for males ≥ 30 mL/minute

5. Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib.

6. Male subjects who are sexually active must agree to use highly effective forms of contraception with the addition of a barrier method (condom) during the study.

7. Men must agree to refrain from sperm donation during the study.

8. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing tablets without difficulty.

9. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion Criteria

1. Evidence of any active concurrent disease (such as severe or uncontrolled systemic diseases that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol.

2. Patients with active Richter's transformation.

3. History of or ongoing confirmed central nervous system (CNS) lymphoma.

4. Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug.

5. Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.

6. History of prior malignancy that could affect compliance with the protocol or interpretation of results in the opinion of the investigator, except for the following:

   1. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix, breast or prostate at any time prior to study that are adequately treated. Patients with cancer not requiring therapy (ex: early prostate cancer under observation, should be discussed with Study PI).
   2. Continuation of maintenance therapy in patients with adequately treated malignancy
   3. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy and/or chemotherapy from which subject is disease-free for ≥3 years without further treatment

7. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening.

   a. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study.

8. Patients with a condition that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment. For example, refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection.

9. Received a live virus vaccination within 28 days of first dose of study drug.

10. Uncontrolled HIV infection.

11. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML).

12. Any active uncontrolled significant infection (e.g., bacterial, viral or fungal), including subjects with positive cytomegalovirus [CMV] DNA polymerase chain reaction [PCR]).

13. Serologic status reflecting active hepatitis B or C infection.

    1. Note: Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
    2. Subjects who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.

14. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.

15. Uncontrolled bleeding diathesis (e.g., hemophilia, von Willebrand disease).

16. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.

    a. Note: DOAC or LMWH are not exclusionary.

17. Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited. Patient who have started those inhibitor or inducers with known dose outside above timeline will follow dose reduction schedule provided in the protocol and package insert of venetoclax and acalabrutinib.

18. Breastfeeding or pregnant.

19. Concurrent participation in another therapeutic clinical trial.

20. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.

21. Requires treatment with P-glycoprotein (P-gp) inhibitor during venetoclax initiating and dose escalation phase.

    Note: After initiation of the study drug(s) once a stable dose is reached if P-gp inhibitors are required then these P-gp inhibitors will be allowed per the reduction tables within the protocol or per the study drug(s) package insert/IB.

22. Patients who are unable to receive Prevnar vaccination.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: intermittent venetoclax	Venetoclax	intermittent venetoclax (7days administration per cycle) + acalabrutinib
Arm A: intermittent venetoclax	Acalabrutinib	intermittent venetoclax (7days administration per cycle) + acalabrutinib
Arm B: continuous venetoclax	Venetoclax	continuous venetoclax (28 days administrations per cycle) + acalabrutinib
Arm B: continuous venetoclax	Acalabrutinib	continuous venetoclax (28 days administrations per cycle) + acalabrutinib

Primary Outcome Measures

Name	Time	Method
Complete Remission defined by the IWCLL 2018 criteria	Post 12 cycles of treatment (each cycle is 28 days)	Complete Remission (CR) as defined by the IWCLL 2018 criteria after 12 cycles of treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.

Secondary Outcome Measures

Name	Time	Method
Circulating numbers of NK cells measured by flow cytometry	Pretreatment, Cycle1, Cycle4, Cycle6, Cycle9, Cycle12 and 3 months after completion of treatment (each cycle is 28 days)	Circulating numbers of NK cells using flow cytometry in both treatment arms at pretreatment, C1, C4, C6, C9, C12 and 3 months after completion of treatment.
Circulating numbers of T cells measured by flow cytometry	Pretreatment, Cycle1, Cycle4, Cycle6, Cycle9, Cycle12 and 3 months after completion of treatment (each cycle is 28 days)	Circulating numbers of T cells using flow cytometry in both treatment arms at pretreatment, C1, C4, C6, C9, C12 and 3 months after completion of treatment.
uMRD Complete Remission (CR) defined by negative luekemia cell to 10-6 using NGS Clonoseq	Post 12 cycles of treatment (each cycle is 28 days)	The rate of uMRD Complete Remission (CR) defined by negative luekemia cell to 10-6 using NGS Clonoseq from bone marrow and peripheral blood samples after 12 cycles of treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.
Rate of Tumor lysis syndrome	Cycle 4 of therapy (each cycle is 28 days); post intervention point of outpatient rapid dose escalation of venetoclax	Tumor lysis syndrome (TLS) after outpatient rapid dose escalation of venetoclax in both treatment arms.
Overall Survival -defined as time from study randomization to death or last follow up	From date of patient baseline visit to death or last follow up (up to 5 years post treatment).	Overall Survival (OS) defined as time from study randomization to death or last follow up
Progression Free Survival (PFS) defined as the time from study randomization to disease progression, death, or last follow up after treatment	From date of patient baseline visit to death or last follow up (up to 5 years post treatment).	Progression Free Survival (PFS) defined as the time from study randomization to disease progression, death, or last follow up after treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.
Response to vaccination measured by Levels of antibody titer	3 months (+/- 1 month) from completion of all treatment.	Levels of antibody titer in response to vaccination with Prevnar 20 at 3 months (+/- 1 month) from completion of all treatment.

Trial Locations

Locations (1)

University of Cincinnati; 🇺🇸 Cincinnati, Ohio, United States